Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing?

被引：15
作者：
Gotte, Matthias [1 ,2 ,3 ]
机构：
[1] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada
[2] McGill Univ, Dept Med, Montreal, PQ, Canada
[3] McGill Univ, Dept Biochem, Montreal, PQ, Canada
来源：
PLOS MEDICINE | 2007年 / 4卷 / 12期
基金：
英国医学研究理事会;
关键词：
D O I：
10.1371/journal.pmed.0040346
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1858 / 1861
页数：4
相关论文
共 25 条
[1]   A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy [J].
Baxter, JD ;
Mayers, DL ;
Wentworth, DN ;
Neaton, JD ;
Hoover, ML ;
Winters, MA ;
Mannheimer, SB ;
Thompson, MA ;
Abrams, DI ;
Brizz, BJ ;
Ioannidis, JPA ;
Merigan, TC .
AIDS, 2000, 14 (09) :F83-F93
[2]   Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3′-azido-3′-dideoxythymidine [J].
Brehm, Jessica H. ;
Koontz, Dianna ;
Meteer, Jeffrey D. ;
Pathak, Vinay ;
Sluis-Cremer, Nicolas ;
Mellors, John W. .
JOURNAL OF VIROLOGY, 2007, 81 (15) :7852-7859
[3]   Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase [J].
Cane, Patricia A. ;
Green, Hannah ;
Fearnhill, Esther ;
Dunn, David .
AIDS, 2007, 21 (04) :447-455
[4]   Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA) [J].
Cingolani, A ;
Antinori, A ;
Rizzo, MG ;
Murri, R ;
Ammassari, A ;
Baldini, F ;
Di Giambenedetto, S ;
Cauda, R ;
De Luca, A .
AIDS, 2002, 16 (03) :369-379
[5]   Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3-Azido-3'-deoxythymidine resistance [J].
Delviks-Frankenberry, Krista A. ;
Nikolenko, Galina N. ;
Barr, Rebekah ;
Pathak, Vinay K. .
JOURNAL OF VIROLOGY, 2007, 81 (13) :6837-6845
[6]   Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial [J].
Durant, J ;
Clevenbergh, P ;
Halfon, P ;
Delgiudice, P ;
Porsin, S ;
Simonet, P ;
Montagne, N ;
Boucher, CAB ;
Schapiro, JM ;
Dellamonica, P .
LANCET, 1999, 353 (9171) :2195-2199
[7]   Prevalence of G333D/E in naive and pretreated HIV-infected patients [J].
Gallego, O ;
Corral, A ;
De Mendoza, C ;
Rodés, B ;
Soriano, V .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (12) :857-860
[8]  
HACHIYA A, 2007, 14 C RETR OPP INF 25
[9]   A mutation in the 3′ region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance [J].
Harrigan, PR ;
Salim, M ;
Stammers, DK ;
Wynhoven, B ;
Brumme, ZL ;
McKenna, P ;
Larder, B ;
Kemp, SD .
JOURNAL OF VIROLOGY, 2002, 76 (13) :6836-6840
[10]   Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1:: 2003 recommendations of an international AIDS Society-USA panel [J].
Hirsch, MS ;
Brun-Vézinet, F ;
Clotet, B ;
Conway, B ;
Kuritzkes, DR ;
D'Aquila, RT ;
Demeter, LM ;
Hammer, SM ;
Johnson, VA ;
Loveday, C ;
Mellors, JW ;
Jacobsen, DM ;
Richman, DD .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (01) :113-128
123